Glossary
1L first-line
2L second-line
AE adverse event
AFP alpha-fetoprotein
ALT alanine aminotransferase
AST aspartate aminotransferase
BCLC Barcelona Clinic Liver Cancer
bid twice daily
BSC best supportive care
BW body weight
CA19-9 carbohydrate antigen 19-9
CAPOX capecitabine-oxaliplatin
CI confidence interval
CRC colorectal cancer
DCR disease control rate
DFS disease-free survival
DoR duration of response
ECOG Eastern Cooperative
Oncology Group
EGFR endothelial growth factor
receptor
EHS extrahepatic spread
FOLFIRI folinic acid + fluorouracil +
irinotecan
(m)FOLFOX (modified) leucovorin +
5-fluorouracil + oxaliplatin
GEJ gastro-oesophageal junction
GI gastrointestinal
HA hyaluronan
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
HER2 human epidermal growth
factor receptor 2
HR hazard ratio
IQR interquartile range
(m)ITT (modified) intent-to-treat
IV intravenous
KPS Karnofsky performance status
MSI microsatellite instability
MVI macroscopic portal vein
invasion
NA not available
NR not reached
ORR overall/objective response
rate
OS overall survival
PD progressive disease
PDA pancreatic ductal
adenocarcinoma
PD-(L)1 programmed death-(ligand) 1
PFS progression-free survival
PK pharmacokinetics
PO orally
PR partial response
PRO patient-reported outcome
PS performance status
q(2/3/4)w every (2/3/4) week(s)
QoL quality of life
R randomised
RECIST Response Evaluation
Criteria In Solid Tumors
RFS relapse-free survival
SAE serious adverse event
SD stable disease
SIRT selective internal radiation
therapy
TEAE treatment-emergent adverse
event
TRAE treatment-related adverse
event
TTP time to progression
TTR time to response
XELOX oxaliplatin + capecitabine